The Fructose and Allulose Catalytic Effects (FACE) Trial

NACompletedINTERVENTIONAL
Enrollment

50

Participants

Timeline

Start Date

November 30, 2015

Primary Completion Date

August 31, 2016

Study Completion Date

August 31, 2016

Conditions
Type 2 Diabetes
Interventions
OTHER

Allulose

"A double-blind, randomized, multiple-crossover equivalence design. Each participant will act as their own control receiving the treatments in random order, each separated by a 1 week washout period. The treatment will be developed by Tate \& Lyle."

OTHER

Fructose

"A double-blind, randomized, multiple-crossover equivalence design. Each participant will act as their own control receiving the treatments in random order, each separated by a 1 week washout period. The treatment will be developed by Tate \& Lyle."

OTHER

Control

"A double-blind, randomized, multiple-crossover equivalence design. Each participant will act as their own control receiving the treatments in random order, each separated by a 1 week washout period. The treatment will be developed by Tate \& Lyle."

Trial Locations (1)

M5C 2T2

The Toronto 3D (Diet, Digestive tract and Disease) Knowledge Synthesis and Clinical Trials Unit, Clinical Nutrition and Risk Factor Modification Centre, St. Michael's Hospital, Toronto

All Listed Sponsors
collaborator

Tate & Lyle

INDUSTRY

lead

University of Toronto

OTHER

NCT02459834 - The Fructose and Allulose Catalytic Effects (FACE) Trial | Biotech Hunter | Biotech Hunter